Cargando…
PFKP is transcriptionally repressed by BRCA1/ZBRK1 and predicts prognosis in breast cancer
OBJECTIVES: The present study aims to elucidate the underlying mechanism how PFKP is regulated by BRCA1 and the clinical significance of PFKP in breast cancer. METHODS: MEF-BRCA1(△/△) and the wild type counterpart MEF-BRCA1(+/+) cell lines were used to test the sensitivity of glucose depletion in cu...
Autores principales: | Yeerken, Danna, Hong, Ruoxi, Wang, Yan, Gong, Ying, Liu, Rui, Yang, Di, Li, Jinting, Fan, Jiawen, Chen, Jie, Zhang, Weimin, Zhan, Qimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259711/ https://www.ncbi.nlm.nih.gov/pubmed/32470015 http://dx.doi.org/10.1371/journal.pone.0233750 |
Ejemplares similares
-
Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation
por: Hong, Ruoxi, et al.
Publicado: (2019) -
Defect of SLC38A3 promotes epithelial-mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma
por: Liu, Rui, et al.
Publicado: (2020) -
A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma
por: Wu, Mengjiao, et al.
Publicado: (2019) -
Corrigendum to “A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma” [EBioMedicine 41 (2019) 244–255]
por: Wu, Mengjiao, et al.
Publicado: (2019) -
Corrigendum to “A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma” [EBioMedicine 41 (2019) 244–255]
por: Wu, Mengjiao, et al.
Publicado: (2021)